6 days ago
Daly City, CA, USA or New York, NY, USAEntry Level / Mid Level
H1B sponsor
Base Salary
$141k - $274k/yr
Responsibilities
- Design, implement, and improve large-scale distributed machine learning systems and core infrastructure.
- Develop strategies to improve model performance on scientific tasks, long-horizon task completion, reasoning, and alignment.
- Translate biological and chemical domain knowledge into machine learning objectives, training signals, and evaluation criteria.
- Design evaluation methodologies, benchmarks, and high-quality datasets for biological research capabilities.
- Collaborate with researchers to convert prototypes and novel algorithms into scalable, production-ready systems.
- Maintain training infrastructure and data pipelines and write clean, efficient code to test research hypotheses.
Requirements
- BS/MS in Computer Science, Statistics, Mathematics, Physics, or a related quantitative field plus 2 or more years of relevant experience, or a PhD with 0–2 years of relevant experience.
- Experience developing and training large-scale machine learning models, including post-training methods for domain knowledge, reasoning, and alignment.
- Strong research record with publications at venues such as NeurIPS, ICLR, or ICML.
- Strong software engineering skills and experience with high-performance computing systems.
- Preferred: experience with protein sequences, chemical graphs, or structured molecular data.
- Preferred: public research portfolio or significant contributions to open-source ML libraries.
Benefits
- Benefits are provided through the company benefits program referenced in the posting.
- Relocation benefits are not available for this position.
- The role is based on a stated primary-location salary structure for New York City or San Francisco.
Categories
AI ResearchML Engineering
About Genentech
Genentech discovers, develops, and commercializes biologic therapies for serious diseases across oncology, immunology, neuroscience, ophthalmology, infectious disease, and metabolism. Founded in 1976 and headquartered in South San Francisco, it operates as a member of the Roche Group, with research centered in its gRED organization and revenue driven by prescription drug sales and collaborations.